CDK9 and breast carcinoma: AZD4573 treatment resulted in decreased phosphorylation of RNAP2 in both sensitive and less-sensitive cell lines, suggesting that AZD4573 successfully inhibits CDK9 activity in breast cancer cell lines (Fig. 1B and S1B).